BridgeBio beats Q2 estimates, confirms $1B+ 2026 sales goal and plans three product launches by 2027.

BridgeBio Pharma reported better-than-expected Q2 results, beating analyst estimates by $24 million. The company reaffirmed its guidance for over $1 billion in global sales of its Attruby and Beyonttra products by 2026. Attruby's U.S. sales surged 311% year-over-year, while Beyonttra royalties outside the U.S. rose 62% sequentially, reflecting growing market share. BridgeBio also raised $1 billion in preferred equity to strengthen its balance sheet and support accelerated commercial and pipeline investments. The company expects to achieve positive cash flow within 3-4 quarters and significant profitability by early 2028, enabling potential share repurchases and further business development.